Following years of consultation and review the TGA has issued two new labelling orders to replace the current Therapeutic Good Order No. 69 for specific medicine labelling requirements:
The creation of separate orders for prescription and non-prescription medicines was implemented to reflect how the products are used and ensure adequate information is available for the safe use of products.
Some key changes introduced in the new TGOs will require that the labels for the majority of products supplied in Australia are revised. These include:
Although the TGA has implemented a 4-year transition period before the new TGOs become mandatory, it is recommended that where new labels are being created, the new TGOs are adhered to now. This will avoid a rush to update labelling at the end of the period.
For currently supplied products, the timing of labelling updates will need to be carefully managed over the transition period to ensure there is minimal write-off of packaging components and the appropriate variation applications are submitted (and approved) in a reasonable time period to ensure continued regulatory compliance.
For assistance in updating or developing medicine labels that comply with the new orders, please contact our expert Regulatory Services team on +61 3 9251 0777.
This article was written by Lynda Notting from our Regulatory Services team